Grifols is a global specialty pharmaceutical company focused on plasma-derived medicines such as immunoglobulins, albumin and clotting factors. It operates a large network of plasma collection centers and also supplies diagnostic products for blood typing and transfusion medicine. Hospitals and healthcare systems are the primary end customers for its therapies and testing solutions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1,786 | — | 60 | — |
| Q2 2025 | 1,891 | — | 117 | — |
| Q4 2025 | 1,981.7 | — | 98.3 | — |
| Q1 2026 | 1,700 | -4.8% | 73 | 21.7% |
| Q2 2026 | 1,874 | -0.9% | 155 | 32.5% |
All markets — KeepWinning global stock screener
Other companies on Bolsa de Madrid: Logista Integral, S.A. (LOG), Acerinox, S.A. (ACX), Enagás, S.A. (ENG), Fluidra, S.A. (FDR), Sacyr, S.A. (SCYR), Colonial SFL, Socimi S. A. (COL)